Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRA...(component of ourinternational cardiovasc...),Health
| HOME >> MEDICINE >> TECHNOLOGY |
component of our international cardiovascular development program. The multiple therapeutic impact of varespladib's mechanism of action provides us with a unique opportunity to develop a first-in-class product targeting a life-threatening coronary event for which there are limited therapeutic options."
"Based upon the success of varespladib in two previous Phase II clinical trials in patients with cardiovascular disease in which it demonstrated lipid-lowering and anti-inflammatory benefits, we look forward to further evaluating the impact of varespladib on the hyper-inflammatory state presented by ACS patients," said Dr. James Pennington, Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc.
About Acute Coronary Syndrome
Acute coronary syndrome is a heart condition characterized by chest pain occurring at rest or upon minimal exertion. This condition is also referred to as unstable angina. If the chest pain is associated with heart muscle damage and heart tracing abnormalities, it is typically classified as a heart attack or myocardial infarction.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a privately-held company committed to
developing and commercializing clinical pharmaceutical products that
address unmet medical needs of patients with life-threatening, chronic and
acute inflammatory diseases and autoimmune disorders. The Company has
acquired from Eli Lilly and Company and Shionogi & Co.‚ Ltd. worldwide
rights (excluding Japan) to a series of clinical and pre-clinical compounds
that inhibit the enzymatic activity of members of the phospholipase (PLA2)
family -- a group of enzymes responsible for the release of arachidonic
acid and subsequent production of leukotrienes‚ prostacyclins and other
mediators of inflammation. These highly potent compounds inhibit novel‚
upstream steps in the inflammation cascade and have the potential to
address a variety of diseases. The company has also acq
'/>"/>
| SOURCE Anthera Pharmaceuticals Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |